SEARCH

SEARCH BY CITATION

References

  • ADAMS, M.D., EARNHARDT, J.T., MARTIN, B.R., HARRIS, L.S., DEWEY, W.L. & RAZDAN, R.K. (1977). A cannabinoid with cardiovascular activity but no overt behavioural effects. Experientia, 33, 12041205.
  • AGURELL, S., HALLDIN, M., LINDGREN, J.E., OHLSSON, A., WIDMAN, M., GILLESPIE, H. & HOLLISTER, L. (1986). Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol. Rev., 38, 2143.
  • BENOWITZ, N.L. & JONES, R.T. (1974). Cardiovascular effects of prolonged delta-9-tetrahydro-cannabinol ingestion. Clin. Pharmacol. Ther., 18, 287297.
  • BISOGNO, T., HANUS, L., DE PETROCELLIS, L., TCHILIBON, S., PONDE, D.E., BRANDI, I., MORIELLO, A.S., DAVIS, J.B., MECHOULAM, R. & DI MARZO, V. (2001). Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br. J. Pharmacol., 134, 845852.
  • BREIVOGEL, C.S., GRIFFIN, G., DI MARZO, V. & MARTIN, B.R. (2001). Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol. Pharmacol., 60, 155163.
  • BUKOSKI, R.D., BÁTKAI, S., JÁRAI, Z., WANG, Y., OFFERTALER, L., JACKSON, W.F. & KUNOS, G. (2002). CB1 receptor antagonist SR141716A inhibits Ca2+-induced relaxation in CB1 receptor-deficient mice. Hypertension, 39, 251257.
  • BUSSE, R., EDWARDS, G., FELETOU, M., FLEMING, I., VANHOUTTE, P.M. & WESTON, A.H. (2002). EDHF: bringing the concepts together. Trends Pharmacol. Sci., 23, 374380.
  • CHAYTOR, A.T., MARTIN, P.E., EVANS, W.H., RANDALL, M.D. & GRIFFITH, T.M. (1999). The endothelial component of cannabinoid-induced relaxation in rabbit mesenteric artery depends on gap junctional communication. J. Physiol., 520, 539550.
  • DE PETROCELLIS, L., BISOGNO, T., MACCARRONE, M., DAVIS, J.B., FINAZZI-AGRO, A. & DI MARZO, V. (2001). The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. J. Biol. Chem., 276, 1285612863.
  • DEUTSCH, D.G., GOLIGORSKY, M.S., SCHMID, P.C., KREBSBACH, R.J., SCHMID, H.H.O., DAS, S.K., DEY, S.K., ARREAZA, G., THORUP, C., STEFANO, G. & MOORE, L.C. (1997). Production and physiological actions of anandamide in the vasculature of the rat kidney. J. Clin. Invest., 100, 15381546.
  • DI MARZO, V., BREIVOGEL, C.S., TAO, Q., BRIDGEN, D.T., RAZDAN, R.K., ZIMMER, A.M. & MARTIN, B.R. (2000). Levels, metabolism and pharmacological activity of anandamide in CB1 cannabinoid receptor knockout mice: evidence for non-CB1, non- CB2 receptor-mediated actions of anandamide in mouse brain. J. Neurochem., 75, 24342444.
  • ELLIS, E.F., MOORE, S.F. & WILLOUGHBY, K.A. (1995). Anandamide and delta 9-THC dilation of cerebral arterioles is blocked by indomethacin. Am. J. Physiol., 269, H1859H1864.
  • FACCI, R., DAL TOSO, R., ROMANELLO, S., BURUANI, A., SKAPER, S.D. & LEON, A. (1995). Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc. Natl. Acad. Sci. U.S.A., 92, 33763380.
  • FELDER, C.C., BRILEY, E.M., AXELROD, J., SIMPSON, J.T., MACKIE, K. & DEVANE, W.A. (1993). Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc. Natl. Acad. Sci. U.S.A., 90, 76567660.
  • FELDER, C.C. & GLASS, M. (1998). Cannabinoid receptors and their endogenous agonists. Annu. Rev. Pharmacol. Toxicol., 38, 179200.
  • FELDER, C.C., JOYCE, K.E., BRILEY, E.M., MANSOURI, J., MACKIE, K., BLOND, O., LAI, Y., MA, A.L. & MITCHELL, R.L. (1995). Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol. Pharmacol., 48, 443450.
  • FORD, W.R., HONAN, S.A., WHITE, R. & HILEY, C.R. (2002). Evidence of a novel site mediating anandamide-induced negative inotropic and coronary vasodilatator responses in rat isolated hearts. Br. J. Pharmacol., 135, 11911198.
  • GATLEY, S.J., LAN, R., VOLKOW, N.D., PAPPAS, N., KING, P., WONG, C.T., GIFFORD, A.N., PYATT, B., DEWEY, S.L. & MAKRIYANNIS, A. (1998). Imaging the brain marijuana receptor: development of a radioligand that binds to cannabinoid CB1 receptors in vivo. J. Neurochem., 70, 417423.
  • GEBREMEDHIN, D., LANGE, A.R., CAMPBELL, W.B., HILLARD, C.J. & HARDER, D.R. (1999). Cannabinoid CB1 receptor of rat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current. Am. J. Physiol., 276, H2085H2093.
  • GLASS, M. & FELDER, C.C. (1997). Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J. Neurosci., 17, 53275333.
  • HANUS, L., BREUER, A., TCHILIBON, S., SHILOAH, S., GOLDENBERG, D., HOROWITZ, M., PERTWEE, R.G., ROSS, R.A., MECHOULAM, R. & FRIED, E. (1999). HU308: a specific agonist for CB2, a peripheral cannabinoid receptor. Proc. Natl. Acad. Sci. U.S.A., 25, 1422814233.
  • HILLARD C.J. (2000). Endocannabinoids and vascular function. J. Pharmacol. Exp. Ther., 294, 2732.
  • HOWLETT, A.C., BARTH, F., BONNER, T.I., CABRAL, G., CASELLAS, P., DEVANE, W.A., FELDER, C.C., HERKENHAM, M., MACKIE, K., MARTIN, B.R., MECHOULAM, R. & PERTWEE, R.G. (2002). International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors. Pharmacol. Rev., 54, 161202.
  • JÁRAI, Z., WAGNER, J.A., VARGA, K., LAKE, K.D., COMPTON, D.R., MARTIN, B.R., ZIMMER, A.M., BONNER, T.I., BUCKLEY, N.E., MEZEY, E., RAZDAN, R.K., ZIMMER, A. & KUNOS, G. (1999). Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc. Natl. Acad. Sci. U.S.A., 96, 1413614141.
  • KAGOTA, S., YAMAGUCHI, Y., MAKAMURA, K., SUGUIRA, T., WAKU, K. & KUNITOMO, M. (2001). 2-Arachidonylglycerol, a candidate of endothelium-derived hyperpolarizing factor. Eur. J. Pharmacol., 415, 233238.
  • KARAKI, H., OZAKI, H., HORI, M., MITSUSAITO, M., AMINO, K.I., HARADA, K.I., MIYAMOTO, S., NAKAZAWA, H., WON, K.J. & SATO, K. (1997). Calcium movements, distribution, and functions in smooth muscle. Pharmacol. Rev., 49, 157230.
  • LAKE, K.D., COMPTON, D.R., VARGA, K., MARTIN, B.R. & KUNOS, G. (1997). Cannabinoid-induced hypotension and bradycardia in rats is mediated by CB1-like cannabinoid receptors. J. Pharmacol. Exp. Ther., 281, 10301037.
  • LAN, R., LIU, Q., FAN, P., LIN, S., FERNANDO, S.R., MCCALLION, D., PERTWEE, R. & MAKRIYANNIS, A. (1999). Structure–activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J. Med. Chem., 42, 769776.
  • LIU, C. & HERMANN, T.E. (1978). Characterization of ionomycin as a calcium ionophore. J. Biol. Chem., 253, 58925894.
  • LIU, H., XIONG, Z. & SPERELAKIS, N. (1997). Cyclic nucleotides regulate the activity of L-type calcium channels in smooth muscle cells from rat portal vein. J. Mol. Cell. Cardiol., 29, 14111421.
  • MANSBACH, R.S., ROVETTI, C.C., WINSTON, E.N. & LOWE, J.A. (1996). Effects of the cannabinoid CB1 receptor antagonist SR141716A on the behaviour of pigeons and rats. Psychopharmacology, 124, 315332.
  • MATSUDA, L.A., LOLAIT, S.J., BROWNSTEIN, M.J., YOUNG, A.C. & BONNER, T.I. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 346, 561564.
  • MISTRY, D.K. & GARLAND, C.J. (1998). Nitric oxide (NO)-induced activation of large-conductance Ca2+-dependent K+ channels (BKCa) in smooth muscle cells isolated from the rat mesenteric artery. Br. J. Pharmacol., 124, 11311140.
  • MOMBOULI, J.V., SCHAEFFER, G., HOLZMANN, S., KOSTNER, G.M. & GRAIER, W.F. (1999). Anandamide-induced mobilization of cytosolic Ca2+ in endothelial cells. Br. J. Pharmacol., 126, 15931600.
  • MUNRO, S., THOMAS, K.L. & ABU-SHAAR, M. (1993). Molecular characterisation of a peripheral receptor for cannabinoids. Nature, 365, 6165.
  • MUPANOMUNDA, M.M., WANG, Y. & BUKOSKI, R.D. (1998). Effect of chronic sensory denervation on Ca2+-induced relaxation of isolated mesenteric resistance arteries. Am. J. Physiol., 274, H1655H1661.
  • MURPHY, M.E. & BRAYDEN, J.E. (1995). Nitric oxide hyperpolarizes rabbit mesenteric arteries via ATP-sensitive potassium channels. J. Physiol., 486, 4758.
  • OMAR, R., BOTTRILL, F.E., HILEY, C.R. & WHITE, R. (2000). Interaction of cyclic cAMP modulating agents with levcromakalim in the relaxation of rat isolated mesenteric artery. Eur. J. Pharmacol., 401, 8596.
  • PRATT, P.F., HILLARD, C.J., EDGEMOND, W.S. & CAMPBELL, W.B. (1998). N-arachidonylethanolamide relaxation of bovine coronary artery is not mediated by CB1 cannabinoid receptor. Am. J. Physiol., 274, H375H381.
  • RALEVIC, V., KENDALL, D.A., RANDALL, M.D., ZYGMUNT, P.M., MOHAVED, P. & HÖGESTÄTT, E.D. (2000). Vanilloid receptors on capsaicin-sensory nerves mediated relaxation to methanandamide in the rat isolated mesenteric arterial bed and small mesenteric arteries. Br. J. Pharmacol., 130, 14831488.
  • RINALDI-CARMONA, M., BARTH, F., MILLAN, J., DEROCQ, J.M., CASELLAS, P., CONGY, C., OUSTRIC, D., SARRAN, M., BOUABOULA, M., CALANDRA, B., PORTIER, M., SHIRE, D., BRELIERE, J.C. & LE FUR, G. (1998). SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther., 284, 644650.
  • RINALDI-CARMONA, M., CALANDRA, B., SHIRE, D., BOUABOULA, M., OUSRTIC, D., BARTH, F., CASELLAS, P., FERRARA, P. & LE FUR, G. (1996). Characterisation of two cloned human CB1 cannabinoid receptor isoforms. J. Pharmacol. Exp. Ther., 278, 871878.
  • ROSS, R.A., BROCKIE, H.C., STEVENSON, L.A., MURPHY, V.L., TEMPLETON, F., MAKRIYANNIS, A. & PERTWEE, R.G. (1999). Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630. Br. J. Pharmacol., 126, 665672.
  • SHIRE, D., CARILLOM, C., KAGHAD, M., CALANDRA, B., RINALDI-CARMONA, M., LE FUR, G., CAPUT, D. & FERRARA, P. (1995). An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J. Biol. Chem., 270, 32763731.
  • SHOWALTER, V.M., COMPTON, D.R., MARTIN, B.R. & ABOOD, M.E. (1996). Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J. Pharmacol. Exp. Ther., 278, 989999.
  • VARGA, K., LAKE, K., MARTIN, B.R. & KUNOS, G. (1995). Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. Eur. J. Pharmacol., 278, 279283.
  • WAGNER, J.A., VARGA, K., JÁRAI, Z. & KUNOS, G. (1999). Mesenteric vasodilation mediated by endothelial anandamide receptors. Hypertension, 33, 429434.
  • WHITE, R. & HILEY, C.R. (1997). A comparison of EDHF-mediated and anandamide-induced relaxations in the rat isolated mesenteric artery. Br. J. Pharmacol., 122, 15731584.
  • WHITE, R. & HILEY, C.R. (1998a). Modulation of relaxation to levcromakalim by S-nitroso-N-acetylpenicallamine (SNAP) and 8-bromo cyclic GMP in the rat isolated mesenteric artery. Br. J. Pharmacol., 124, 12191226.
  • WHITE, R. & HILEY, C.R. (1998b). The actions of some cannabinoid receptor ligands in rat isolated mesenteric artery. Br. J. Pharmacol., 125, 533541.
  • WHITE, R. & HILEY, C.R. (1998c). The actions of the cannabinoid receptor antagonist, SR 141716A, in the rat isolated mesenteric artery. Br. J. Pharmacol., 125, 689696.
  • WHITE, R. & HILEY, C.R. (2000). Hyperpolarisation of rat mesenteric endothelial cells by ATP-sensitive K+ channel openers. Eur. J. Pharmacol., 397, 279290.
  • WHITE, R., HO, W.-S.V., BOTTRILL, F.E., FORD, W.R. & HILEY, C.R. (2001). Mechanisms of anandamide-induced vasorelaxation in rat isolated coronary arteries. Br. J. Pharmacol., 134, 921929.
  • ZYGMUNT, P.M., EDWARDS, G., WESTON, A.H., LARSSON, B., HÖGESTÄTT, E.D. (1997). Involvement of voltage-dependent potassium channels in the EDHF-mediated relaxation of rat hepatic artery. Br. J. Pharmacol., 121, 141149.
  • ZYGMUNT, P.M., PETERSSON, J., ANDERSSON, D.A., CHUANG, H., SØRGÅRD, M., DI MARZO, V., JULIUS, D. & HÖGESTÄTT, E.D. (1999). Vanilloid receptors on sensory nerves mediate vasodilator action of anandamide. Nature, 400, 452457.